Navigation Links
New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
Date:9/26/2011

of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... 19, 2014 Intarcia Therapeutics, Inc. ... for its lead candidate ITCA 650 (continuous subcutaneous delivery ... baseline HbA1c levels at the 50 th Annual ... Diabetes (EASD). Data from the open-label, phase 3 FREEDOM-HBL ... sugar in patients with poorly controlled type 2 diabetes. ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... , SAN DIEGO, Sept. 8 ... ("Stemedica"), a world leader in stem cell research and manufacturing, ... and Trademark Office ("USPTO") for a proprietary methodology in the ... the USPTO on August 27th of this year. The ...
... MELBOURNE, Australia, Sept. 3 Cytopia Limited,s (ASX: CYT) ... Food and Drug Administration (FDA) review. CYT387 is a small-molecule ... The company,s IND application is now active and Cytopia is ... United States. , , CYT387 will be ...
Cached Medicine Technology:United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy 2United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy 3Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials 2
(Date:9/21/2014)... (PRWEB) September 21, 2014 "I wanted ... without having to consume sugary, foul-tasting energy drinks," said ... not always just want to drink plain, old coffee. ... energy booster." , He developed ENERG CHEWING GUM to ... with weight loss. The formula contains nutritious vitamins, minerals ...
(Date:9/21/2014)... The Illinois Joining Forces Behavioral ... statewide symposium ( tinyurl.com/ILBHC14 ) focused on improving ... Sponsored by the VNA Foundation, Thresholds, Illinois Department ... Health & Disability Advocates, the symposium will be ... in Springfield, IL. The symposium features keynote ...
(Date:9/21/2014)... 21, 2014 The Electronic Medical ... supports electronic medical records (EMR) and electronic health ... healthcare legislation during the past five years and ... the five years to 2019. The 2009 Health ... established Medicare and Medicaid incentives to encourage the ...
(Date:9/21/2014)... Discount-Dress.com, a company that specializes in fashion garments ... implement a new shopping cart software on its website. ... Furthermore, the company has unveiled a new collection of ... items come in fashionable designs; all of them are ... off. "We are happy to release the new beach ...
(Date:9/21/2014)... accommodate the ever-growing customer base, Angeldress.co.uk decided to implement ... the company has unveiled its 2014 vintage wedding ... gowns, Angeldress.co.uk wants to make sure that all customers ... Its high quality vintage wedding outfits are now available ... off. , Online shopping is becoming more and more ...
Breaking Medicine News(10 mins):Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2
... , ... procedure to reshape the inner vaginal lips, may be considered medically necessary when large or ... cases like these, Chicago-area plastic surgeon Allan Parungao, MD, works with patients to help get ... ...
... Readers can ... Maroema Cook Book” by Mamta Reid of Tokyo’s MAROEMA Vegetarian Catering. , ... (PRWEB) May 6, 2010 -- Individuals looking for ... of “A must have...The Maroema Cook Book” by Mamta Reid. With a lightweight, compact design ...
... with dementia are six times more likely to develop the ... to results of a 12-year study led by Johns Hopkins, ... the researchers saw among caregivers was on par with the ... Alzheimer,s disease, they report in the May Journal of ...
... 6, 2010 Results from the SPIRIT IV clinical ... Therapeutics (TCT) 2009 scientific symposium, were published today in ... Data from the trial, a large-scale multi-center study of ... stents demonstrated enhanced safety and efficacy in the treatment ...
... outbreak began, finds this flu had new targets , WEDNESDAY, ... flu first appeared, the World Health Organization has issued perhaps ... , "Here,s the definitive reference that shows in black-and-white what ... Dr. John Treanor, a professor of medicine and of microbiology ...
... ... the Global Embolization Symposium and Technologies (GEST) Meeting. Focus is on Benefit of Embolization ... ... a U.S.-based subsidiary of Terumo Corporation, today announced its educational program for the 4th ...
Cached Medicine News:Health News:Labiaplasty May Be Covered by Insurance, Notes Chicago-area Plastic Surgeon Allan Parungao, MD 2Health News:Labiaplasty May Be Covered by Insurance, Notes Chicago-area Plastic Surgeon Allan Parungao, MD 3Health News:Labiaplasty May Be Covered by Insurance, Notes Chicago-area Plastic Surgeon Allan Parungao, MD 4Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 2Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 3Health News:Spouses who care for partners with dementia at sixfold higher risk of same fate 2Health News:Spouses who care for partners with dementia at sixfold higher risk of same fate 3Health News:Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent 2Health News:H1N1 Often Hit the Young and Healthy 2Health News:H1N1 Often Hit the Young and Healthy 3Health News:Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting 2Health News:Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting 3Health News:Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting 4
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
Medicine Products: